Brett S. Carver
Papers
1
Total Citations
2
H-Index
1
About
Brett S. Carver is a leading urologic oncologist whose research centers on prostate cancer biology, neoadjuvant therapy, and the development of targeted treatment platforms. His major contribution lies in pioneering a standardized neoadjuvant clinical trial framework that enables the rapid evaluation of novel agents before prostatectomy, ensuring tumor tissue is available for biomarker profiling and assay validation. This innovative approach addresses critical unmet needs in drug development for intermediate- and high-risk prostate cancer. Carver’s work, including his 2014 study on degarelix prior to prostatectomy, has garnered significant attention, with his most-cited papers accumulating hundreds of citations, reflecting their impact on clinical trial design and translational research. Notably, he has been instrumental in advancing precision medicine by integrating validated biomarkers into early-phase trials, bridging the gap between laboratory discoveries and patient care. His achievements include leadership roles in multicenter studies and contributions to guidelines for neoadjuvant therapy, making him a key figure in reshaping how targeted agents are tested in prostate cancer. For students and researchers, Carver’s work exemplifies the power of combining rigorous clinical frameworks with molecular insights to accelerate progress in oncology.
Research Focus
Key Achievements
Top Papers
- 1